CPMD
CannaPharmaRX, Inc. [CPMD] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
CPMD Stock Summary
In the News
CPMD Financial details
Company Rating
Sell
Market Cap
4.73M
Income
-7.5M
Revenue
24.95K
Book val./share
-0.07
Cash/share
-0.02
Dividend
-
Dividend %
-
Employees
6
Optionable
No
Shortable
Yes
Earnings
22 Sep 2023
P/E
-0.03
Forward P/E
-
PEG
0
P/S
11.95
P/B
-0.01
P/C
-0.73
P/FCF
-0.2
Quick Ratio
-0.28
Current Ratio
-
Debt / Equity
-0.8
LT Debt / Equity
-0.27
-
-
EPS (TTM)
-0.03
EPS next Y
-
EPS next Q
-
EPS this Y
-71.14%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-69.84%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-145%
ROE
39%
ROC
0.36%
Gross Margin
40%
Oper. Margin
-21978%
Profit Margin
-30039%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
7.0E-4-0.0279
52W High
-
52W Low
-
RSI
49.58
Rel Volume
0.15
Avg Volume
2.68M
Volume
406.2K
Perf Week
-14.71%
Perf Month
11.54%
Perf Quarter
107.14%
Perf Half Y
81.25%
-
-
-
-
Beta
-1190.54
-
-
Volatility
0%, 0%
Prev Close
-3.33%
Price
0.0145
Change
20.83%
CPMD Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.17 | -0.8 | -0.55 | -0.14 | -0.04 | |
| Operating cash flow per share | -0.05 | -0.12 | -0.01 | -0.03 | -0.01 | |
| Free cash flow per share | -0.05 | -0.12 | -0.01 | -0.03 | -0.01 | |
| Cash per share | 0.03 | 0.04 | 0.01 | 0 | 0 | |
| Book value per share | -0.02 | 0.16 | -0.22 | -0.17 | -0.08 | |
| Tangible book value per share | -0.46 | -0.11 | -0.22 | -0.17 | -0.08 | |
| Share holders equity per share | -0.02 | 0.16 | -0.22 | -0.17 | -0.08 | |
| Interest debt per share | 0.63 | 0.44 | 0.3 | 0.14 | 0.08 | |
| Market cap | 30.54M | 39.28M | 19.94M | 967.19K | 2.11M | |
| Enterprise value | 39.27M | 48.56M | 29.61M | 9.96M | 16.63M | |
| P/E ratio | -9.87 | -1.58 | -0.9 | -0.09 | -0.25 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -32.45 | -10.35 | -35.39 | -0.4 | -1.46 | |
| PFCF ratio | -32.45 | -10.22 | -35.39 | -0.4 | -1.35 | |
| P/B Ratio | -106.66 | 8.09 | -2.27 | -0.07 | -0.12 | |
| PTB ratio | -106.66 | 8.09 | -2.27 | -0.07 | -0.12 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -73.73 | -17.03 | -6.57 | -3.81 | -3.68 | |
| EV to operating cash flow | -41.73 | -12.8 | -52.54 | -4.12 | -11.48 | |
| EV to free cash flow | -41.73 | -12.64 | -52.54 | -4.11 | -10.63 | |
| Earnings yield | -0.1 | -0.63 | -1.11 | -10.69 | -4.04 | |
| Free cash flow yield | -0.03 | -0.1 | -0.03 | -2.5 | -0.74 | |
| Debt to equity | -32.14 | 1.91 | -1.14 | -0.7 | -0.84 | |
| Debt to assets | 0.91 | 0.58 | 1.14 | 78.89 | 2.68 | |
| Net debt to EBITDA | -16.4 | -3.25 | -2.14 | -3.44 | -3.22 | |
| Current ratio | 0.1 | 0.49 | 0.03 | 0 | 0.01 | |
| Interest coverage | -0.45 | -3.57 | -6.32 | -1.99 | -2.28 | |
| Income quality | 0.3 | 0.19 | 0.03 | 0.27 | 0.17 | |
| Dividend Yield | 0 | 0.07 | 0 | 0 | 0 | |
| Payout ratio | 0 | -0.11 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.79 | 0.51 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0.01 | 0 | 0 | 0.08 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | -0.36 | 0 | -2.31 | -0.39 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.25 | 1.67 | 1.63 | 0.73 | 0.27 | |
| ROIC | -0.18 | -1.38 | -13.47 | 0.9 | -2.47 | |
| Return on tangible assets | -1.43 | -3.19 | -2.54 | -90.44 | -1.58 | |
| Graham Net | -0.55 | -0.32 | -0.42 | -0.17 | -0.11 | |
| Working capital | -5.36M | -2.02M | -17.08M | -13.01M | -17.07M | |
| Tangible asset value | -8.22M | -3.35M | -8.8M | -12.93M | -17.34M | |
| Net current asset value | -9.79M | -9.23M | -17.08M | -13.01M | -22.66M | |
| Invested capital | -32.14 | 1.91 | -1.14 | -0.7 | -0.84 | |
| Average receivables | 0 | 14.18K | 14.46K | 1.16K | 12.51K | |
| Average payables | 685.37K | 834.53K | 1.68M | 2.79M | 5.01M | |
| Average inventory | 0 | -14.18K | -14.46K | -1.16K | 33.38K | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 2.55K | 6.95K | 79.52K | 8.52K | |
| Days of inventory on hand | 0 | -80.22 | -1.57 | -45 | 84.82 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0.14 | 0.05 | 0 | 0.04 | |
| Inventory turnover | 0 | -4.55 | -233.22 | -8.11 | 4.3 | |
| ROE | 10.81 | -5.13 | 2.52 | 0.8 | 0.49 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.01 | -0.01 | 0 | -0.01 | 0 | |
| Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Cash per share | 0 | 0 | 0 | 0 | -0.02 | |
| Book value per share | -0.06 | -0.06 | -0.06 | -0.07 | -0.07 | |
| Tangible book value per share | -0.06 | -0.06 | -0.06 | -0.07 | -0.07 | |
| Share holders equity per share | -0.06 | -0.06 | -0.06 | -0.07 | -0.07 | |
| Interest debt per share | 0.06 | 0.06 | 0.05 | 0.05 | 0.06 | |
| Market cap | 3.35M | 2.74M | 2.64M | 2.7M | 4.13M | |
| Enterprise value | 17.6M | 17.26M | 17.76M | 18.5M | 26.39M | |
| P/E ratio | -0.41 | -0.19 | -0.47 | -0.36 | -1.83 | |
| Price to sales ratio | 0 | 109.8 | 0 | 0 | 0 | |
| POCF ratio | -9.9 | -6.45 | -4.31 | -5.59 | 33.35 | |
| PFCF ratio | -8.71 | -6.32 | -4.3 | -4.85 | 34.52 | |
| P/B Ratio | -0.22 | -0.16 | -0.14 | -0.13 | -0.2 | |
| PTB ratio | -0.22 | -0.16 | -0.14 | -0.13 | -0.2 | |
| EV to sales | 0 | 691.77 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -34.35 | -6.33 | -27.45 | -22.59 | -57.93 | |
| EV to operating cash flow | -51.99 | -40.67 | -29.03 | -38.37 | 213.02 | |
| EV to free cash flow | -45.75 | -39.81 | -28.99 | -33.27 | 220.46 | |
| Earnings yield | -0.61 | -1.33 | -0.54 | -0.7 | -0.14 | |
| Free cash flow yield | -0.11 | -0.16 | -0.23 | -0.21 | 0.03 | |
| Debt to equity | -0.95 | -0.84 | -0.83 | -0.79 | -0.8 | |
| Debt to assets | 2.63 | 2.68 | 2.88 | 2.98 | 3.2 | |
| Net debt to EBITDA | -27.81 | -5.32 | -23.38 | -19.3 | -48.86 | |
| Current ratio | 0.01 | 0.01 | 0.01 | 0 | 0 | |
| Interest coverage | -1.33 | -3.78 | -1.57 | -2.51 | -1.88 | |
| Income quality | 0.26 | 0.12 | 0.43 | 0.26 | -0.22 | |
| Dividend Yield | 0 | 0.07 | 0 | 0 | 0 | |
| Payout ratio | 0 | -0.05 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 125.01 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.14 | 0.02 | 0 | 0.15 | -0.03 | |
| Capex to revenue | 0 | -0.37 | 0 | 0 | 0 | |
| Capex to depreciation | -1.99 | -0.12 | -0.15 | -12.09 | -0.02 | |
| Stock based compensation to revenue | 0 | 1.81 | 0 | 0 | 0 | |
| Graham number | 0.11 | 0.14 | 0.08 | 0.1 | 0.05 | |
| ROIC | -0.19 | -1.55 | -0.38 | -0.72 | -0.67 | |
| Return on tangible assets | -0.38 | -0.67 | -0.27 | -0.35 | -0.11 | |
| Graham Net | -0.08 | -0.08 | -0.08 | -0.08 | -0.1 | |
| Working capital | -14.83M | -17.07M | -17.73M | -19.61M | -20.17M | |
| Tangible asset value | -14.98M | -17.34M | -18.21M | -20.14M | -20.63M | |
| Net current asset value | -20.3M | -22.66M | -23.38M | -25.42M | -25.73M | |
| Invested capital | -0.95 | -0.84 | -0.83 | -0.79 | -0.8 | |
| Average receivables | 15.26K | 20.13K | 26.43K | 35.94K | 48.29K | |
| Average payables | 4.21M | 5.62M | 7.03M | 7.47M | 7.77M | |
| Average inventory | 29.11K | 70.14K | 19.46K | -35.94K | 2.82M | |
| Days sales outstanding | 0 | 83.86 | 0 | 0 | 0 | |
| Days payables outstanding | 128.81K | 49.65K | 249.15K | 69.94M | 58.29M | |
| Days of inventory on hand | 2.13K | 494.39 | -1.03K | -380.35K | 42.68M | |
| Receivables turnover | 0 | 1.07 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0.04 | 0.18 | -0.09 | 0 | 0 | |
| ROE | 0.14 | 0.21 | 0.08 | 0.09 | 0.03 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
CPMD Frequently Asked Questions
What is CannaPharmaRX, Inc. stock symbol ?
CannaPharmaRX, Inc. is a CA stock , located in Calgary of Ab and trading under the symbol CPMD
What is CannaPharmaRX, Inc. stock quote today ?
CannaPharmaRX, Inc. stock price is $0.0145 today.
Is CannaPharmaRX, Inc. stock public?
Yes, CannaPharmaRX, Inc. is a publicly traded company.
Company Profile
- Volume Average 2.68M
- Market Capitalization 4.73M
- Employee 6
- CEO Mr. Dean P. Medwid
- Headquarters Calgary,AB,CA
- IPO Date 1999-10-29
-
Website
https://www.cannapharmarx.com 
CannaPharmaRX, Inc. operates in the cannabis industry in Canada. It negotiates, acquires, and develops various cannabis cultivation projects. The company was incorporated in 1998 and is based in Calgary, Canada.
